Sponsored Links

Bharat Biotech Begins Phase I Clinical Trials Of HN-VAC - Its Cell Culture H1N1 Vaccine PDF Print E-mail
Medical News - General Medical News - end 2009
Bharat Biotech today announced that it has commenced Phase I clinical evaluation of HN-VAC, its cell culture based H1N1 vaccine candidate. Bharat Biotech received the nod from Drugs Controller General of India (DCGI) to conduct the Phase I clinical trials. This vaccine under development will boost immunity against the new H1N1 influenza strains, and help protect public health as the pandemic evolves...


Read more: Health News from Medical News Today